INTRODUCTION
Neutrophils are the principal effectors of the innate immune response and play a critical role in host defence against invading microbes. Hence, patients displaying a defect in either the number or function of these cells are highly vulnerable to recurrent and often fatal bacterial and fungal infection. To perform their bactericidal functions efficiently, neutrophils need to be highly motile, responsive to the finest of chemotactic trails and fully 'armed' to permit efficient intracellular killing. Mechanisms are also needed to prevent premature or excessive activation and to allow efficient removal of cells at the termination of the inflammatory response. Failure of any one of these processes can lead to prolonged residency and activation of neutrophils within tissues and the uncontrolled release of an array of noxious granule proteins and proinflammatory mediators.
Neutrophil priming refers to a process whereby exposure of these cells to a variety of inflammatory mediators or physico-chemical perturbations increases subsequent agonist-induced responses [1] . Priming has direct effects on neutrophil shape, deformability, cell adhesion molecule expression and longevity, and as a consequence has a profound impact on the rheological, adhesive and survival properties of neutrophils. Critically, priming has been shown to be an absolute requirement for neutrophil-mediated tissue injury [2] .
Priming is not a simple 'on-off' phenomenon, but a continuum of responses, determined by the nature, concentration, duration and combination of priming agents [3] . In-vitro studies of priming often employ single primer/activator combinations at maximal concentrations, but in-vivo inflammatory sites are dynamic, with multiple proinflammatory mediators coexisting, resulting in a varied and evolving pattern of primed phenotypes, which are both finely balanced and context dependent [4] .
The intracellular signalling pathways activated by this wide variety of priming responses are likewise complex and varied, with different functional outputs such as enhanced degranulation or reactive oxygen species (ROS) generation; there is a degree of synergy and redundancy, allowing convergence on the final effector functions and culminating in full activation of neutrophils [5] .
Priming thus sits at the interface between neutrophil-mediated benefit and harm. This paradigm is exemplified by a study in which restricting entry of primed neutrophils into the mouse lung was protective in the setting of lipopolysaccharideinduced lung injury, but detrimental in influenza A infection [6] . However, the lack of a consensus definition of priming, the uncertainty as to the best read-out of the primed state and the dynamic nature of neutrophil responses all make this process challenging to study in humans. Here, we describe the role of priming and its role in diverse pathophysiological conditions, focusing on studies in humans rather than animal models, with illustrative examples rather than in comprehensive review of all priming scenarios.
LOCAL AND SYSTEMIC NEUTROPHIL PRIMING
Neutrophils may become primed by systemic factors within the circulation, by the process of transmigration and by interactions with other cells or matrix proteins, or locally at the inflammatory site to which they have been recruited.
Systemically primed neutrophils have been detected in the circulation of patients with a wide range of acute and chronic conditions, including sepsis [7] , vasculitis [8] , exacerbations of chronic obstructive pulmonary disease (COPD) [9] and myeloproliferative disease [10] . Often this reflects circulating inflammatory mediators, but in other contexts disease-associated genetic polymorphisms drive systemic neutrophil priming [11] .
Neutrophils interact with other circulating immune cells. In whole blood, lipopolysaccharide (LPS) primed neutrophils promote neutrophil-platelet interactions [12] and activated platelets release a range of neutrophil priming agents to promote thrombo-inflammatory cascades [13] . Furthermore, primed neutrophils were shown to 'scan' for activated platelets within venules, with this interaction promoting neutrophil transmigration [14] .
Priming may also enhances the release of neutrophil extracellular traps (NETs), expulsions of DNA imbedded in proteases and histones [15] . Intravascular NETs have been detected in patients with sepsis [16] and may be linked to prognosis [17 & ]. Primed neutrophils have also been shown to interact with circulating monocytes and promote transendothelial migration [18 & ] with the potential to cause vascular occlusion and organ damage. In contrast, earlier research showed the full activation of neutrophils (forming NETs) by platelets, which were activated with LPS via TLR4 [19] . This reflects the correlation between TLR4 expression levels on platelets with septic thrombocytopenia, which itself correlated with a poorer prognosis of the disease [20] .
Local neutrophil priming and adhesion are reciprocally interactive processes. Activated endothelial cells display priming agents on their surface, and interaction with the endothelium initiates priming during adhesion or transmigration [21] . Primed/activated neutrophils also degrade matrix proteins, generating chemoattractant 'matrikines' such as proline-glycine-proline (PGP), establishing a 'vicious cycle' of damage and recruitment [22] Such factors, in addition to the local cytokine environment, may contribute to local priming, demonstrated by the comparison of neutrophils isolated from peripheral blood and synovial fluid of patients with rheumatoid and spondyloarthropathy [23] . In other scenarios, systemic priming may promote neutrophil recruitment, with further modulation of neutrophil function at the local inflamed site, for example in acute respiratory distress syndrome [24] and coronary artery disease [25] .
PRIMING IN PATHOPHYSIOLOGICAL CONDITIONS

Trauma
Major trauma induces neutrophil priming in proportion to the magnitude of the traumatic insult [26] . Priming and activation of the innate immune system, along with a multitude of alterations in the KEY POINTS Priming in neutrophils is described as a state of high alert and can influence neutrophil effector functions.
Here, we summarize recent data describing neutrophil priming in vivo, including neutrophils' helpful and harmful role in health and pathophysiological conditions, including trauma, sepsis, ARDS, autoimmune disorders, haematological diseases and cancer.
We also highlight recent advances on finding the correlation between the primed state of neutrophils and disease prognosis as well as clinical interventions.
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adaptive immune response, are well recognized in many forms of trauma, and lead to the clinical syndromes of systemic inflammatory response syndrome and the reciprocal compensated anti-inflammatory response syndrome [27] . Trauma patients with circulating primed neutrophils who encounter a second challenge (e.g. surgery, infection or haemorrhage) were more likely to develop multiorgan failure (MOF) [28] . This 'double-hit' model has recently been recapitulated in a mouse model, when cerebral concussion was found to prime neutrophils, with subsequent minor pulmonary microaspiration inducing massive neutrophil influx and pulmonary haemorrhage [29 & ]. A prospective study of blunt trauma patients correlated the presence of neutrophil priming with increased morbidity and MOF [30] . In contrast, although penetrating thoracic trauma was associated with neutrophil priming within 3 h, there were no adverse consequences in the majority of patients [31] . In some cases, trauma has been associated with blunting of neutrophil responses rather than with priming. This may in part reflect the variation in the scope and nature of trauma, but also temporal evolution, with initial neutrophil priming but subsequent hyporesponsiveness and the heterogeneity of neutrophil phenotypes in vivo [32] . Overall, evidence from human studies suggests that major trauma results in systemic neutrophil priming, the degree of which may correlate with adverse outcomes.
Sepsis
Sepsis is a complex syndrome resulting from a dysregulated host response to infection [33] . Bass et al. first reported neutrophil priming in sepsis and observed that the size of the primed neutrophil population varied widely between patients (range 0-80%) [34] . Other investigators have reported that sepsis in humans is associated with priming [35 & ]. Consistent with findings from studies of trauma, as sepsis evolves, the systemic inflammatory milieu and hence the functional status of intravascular neutrophils may alter [36] . Accumulation of highmobility group box1 protein [37] and dysfunctional responses to complement [38] have been suggested to contribute to alterations in response.
The heterogeneous nature and unpredictable onset sepsis, combined with the complex and varied treatments, make it challenging to establish causality even in animal models. However, noting that only polymorphonuclear neutrophils (PMN) from donors with a common TLR1 single-nucleotide polymorphism (SNP) PMN were effectively primed by the TLR1 agonist Pam3CSK4, Whitmore et al. [7] showed that the same SNP was associated with prolonged length of intensive care unit stay in children with sepsis.
Acute respiratory distress syndrome
The acute respiratory distress syndrome (ARDS) is characterized by diffuse alveolar injury with predominantly neutrophil infiltration, impaired gas exchange and refractory hypoxemia, and can complicate a wide range of insults including sepsis and trauma. Animal models have implicated neutrophil priming and activation as key events in the immune-pathogenesis of acute lung injury.
Priming is required for maximal neutrophil degranulation and release of granular contents such as elastase. Idell et al. [39] demonstrated abundant elastase in bronchoalveolar lavage fluid (BAL) from patients with ARDS, with the concentration correlating with ARDS severity. Inhibiting neutrophil degranulation has shown to prevent the neutrophil priming observed in animal model of sepsis and ARDS [40] .
We and other authors have compared circulating healthy neutrophils with circulating and BAL neutrophils from ARDS patients and observed alterations in neutrophil adhesion molecule expression, primed ROS production and rates of apoptosis [24] . We have also demonstrated that neutrophils primed ex vivo and reinjected into healthy human volunteers are retained within the pulmonary vasculature, and later released in a deprimed state; analysis of neutrophils from the arterial and venous circulation of patients with ARDS suggests that this protective depriming mechanism is lost in this setting [4] .
Autoimmune disorders
Autoimmune diseases are characterized by loss of self-tolerance to a range of antigens, leading to diverse patterns of multiorgan involvement. Neutrophils may both incite autoimmunity and mediate tissue injury.
Antineutrophil cytoplasmic autoantibodies (ANCAs) are associated with a spectrum of necrotizing vasculitis including granulomatosis with polyangiitis and microscopic polyangiitis. Circulating PMN in patients with ANCA-associated vasculitis (AAV) is primed, with enhanced ROS generation and surface expression of proteinase 3 and myeloperoxidase, the antigens of the pathogenic autoantibodies [8] . Furthermore, patient-derived ANCA can activate primed neutrophils [8, 41] . Thus, primed neutrophils are implicated in initiation and propagation of AAV. However in contrast to 'classical' priming, cells displayed accelerated apoptosis [8] . The circulating neutrophil phenotype in AAV thus warrants more detailed characterization.
Rheumatoid arthritis (RA) is a multisystem autoimmune disease with a predilection for synovial joints, and is associated with a number of autoantibodies. Synovial tissues in RA are abundantly infiltrated by neutrophils. Peripheral blood neutrophils from RA patients have been reported to primed [42] , or not [43] , for enhanced ROS production. Several studies have observed the presence of primed and/or activated neutrophils in association with enhanced ROS production in the synovial fluid of rheumatoid joints [23, 44] , alongside the detection of neutrophil-derived proteases and matrix metalloproteases [45] . Of note, the rheumatoid joint is a profoundly hypoxic environment, and hypoxia may augment cytokine priming of neutrophil degranulation [46] .
Haematological diseases
Priming may enhance the ability of neutrophils to interact with other cells such as platelets and endothelial cells to promote thromboinflammatory events. Sickle cell disease (SCD) displays red blood cell fragility with recurrent sickle cell crises which result in vaso-occlusion. Inflammatory and infection mechanisms appear to participate in the vasoocclusive process. Neutrophils from stable SCD patients display enhanced integrin-mediated adhesion to vascular endothelium [47, 48] . Basal protein kinase B (AKT) phosphorylation, consistent with a primed phenotype, was seen in neutrophils isolated from patients with SCD [49] . These observations may have been of therapeutic importance as treating neutrophils isolated from patients with SCD with an AKT inhibitor prevented heterotypic aggregate formation under shear conditions, and reduced intravascular cell-cell interactions in a humanized transgenic mouse model [49,50 & ]. However, SCD neutrophils do not display the full functional profile associated with in-vitro priming; for example defective priming of ROS generation has been reported [51] , perhaps contributing to the increased risk of infection in these vulnerable patients.
Myeloproliferative disorders (MPDs) such as polycythemia vera (PV) and essential thrombocythemia occur secondary to acquired haematopoietic stem cell dysfunction. A mutation (V617F) in the gene encoding Janus kinase 2 (JAK2), which is involved in hematopoietic growth factor signalling, has been found in most PV and about half those with thrombocythemia have the same JAK2 mutation. Patients with MPD also exhibit a marked prothrombotic tendency. In contrast to SCD, neutrophils from patients with the V617F mutation are constitutively primed for ROS generation, mediated by basal phosphorylation of the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase component p47phox on Ser345 [10] . Although basal and stimulated ROS production were dramatically increased, there was only a minor increase in surface CD11b expression. In contrast to MPD, myelodysplastic syndromes (MDSs) are characterized by a differentiation defect in the stem cell compartment, resulting in a disturbed proliferation and differentiation of the erythroid, myeloid or megakaryocytic lineage. Neutrophils from MDS patients show defective priming of the oxidative burst [52] associated with disturbed intracellular signalling and impaired phosphorylation events [52] . This defect in priming was speculated to contribute to the enhanced susceptibility to infection seen in MDS patients, but this was not directly tested.
CANCER
Recent years have seen an increase in interest in the role of neutrophils in regulating solid tumour progression and metastases. The role of tumour-associated neutrophils (TANs) has been recently reviewed [53] . Without manipulation of their phenotype, the overall impact of TANs seems to promote tumour growth and metastasis; for example neutrophilderived proteases and NETs promote tumour progression and/or metastasis [54] . However, TANs exhibit functional plasticity and can be polarized to an N1 (antitumor) or N2 (protumoral) phenotype by the tumour microenvironment or experimental manipulation. N1 neutrophils display some features associated with priming such as increased CD11b cell surface expression. N1 neutrophils are highly cytotoxic to tumour cells, with enhanced generation of ROS which can be prevented by antioxidant treatment [55] . Nitric oxide release by neutrophils was shown to promote cancer cell killing, limit tumour progression and metastasis [56] . Type 1 interferon treatment polarized neutrophils to an N1 phenotype in mice; however, adjunctive interferon treatment in patients with melanoma modulated only a limited subset of N1-neutrophils and did not increase cytotoxicity towards tumour cells [57] . In a mouse model, local radiotherapy recruited tumoricidal CD11b high neutrophils, and this effect was enhanced by concurrent administration of granulocyte colony-stimulating factor [58] ; however, such studies are yet to be translated into humans. Our understanding of the role of neutrophils in cancer is in its infancy and a greater depth of knowledge in particular is required before therapeutic manipulation of these cells is a realistic immunotherapeutic strategy [58] .
